临床研究显示曲妥珠单抗与化疗联合用于人表皮生长因子受体2(HER2)+转移性乳腺癌的治疗以及早期乳腺癌的新辅助和辅助治疗,能显著延长患者的生存时间.其与内分泌治疗联合治疗HER2+且雌激素受体阳性的转移性乳腺癌,疗效优于单纯内分泌治疗.曲妥珠单抗联合其他靶向治疗药物,能够逆转肿瘤对曲妥珠单抗的耐药.疾病进展后继续应用曲妥珠单抗仍可使患者生存受益.Clinical studies have shown that trastuzumab combined with chemotherapy can significantly improve survival in treatment of HER2-positive metastatic breast cancer as well as in the neoadjuvant and adjuvant therapy for HER2-positive early breast cancer. In patients with HER2-positive and hormone receptor-positive metastatic breast cancer, adding trastuzumab to endocrine therapy improves treatment efficacy. Resistance to trastuzumab may be reversed by incorporating other targeted therapeutic drugs. Patients can still benefit from continuing trastuzumab after their disease ...
Targeted therapies are causing a dramatic change in cancer drug development. Trastuzumab, a humanise...
近年来,HER2及其单克隆抗体trastuzumab(商品名Herceptin)是乳腺癌研究的热点之一.被认为是一新的判断乳腺癌预后的独立标志物和治疗靶点.抗HER2的单抗trastuzumab对晚期...
Overexpression of the receptor for human epidermal growth factor type 2 (HER2), or gene amplificatio...
Objective: To observe the efficacy and safety of trastuzumab combined with chemotherapy in patients ...
HER2阳性乳腺癌分子靶向治疗一线药物(曲妥珠单抗)的耐药现象一直是临床治疗的难题.主要机制有曲妥珠单抗与HER2的有效结合受阻;PI3K/AKT/mTOR信号通路异常活化;IGF-1R高水平表达、上...
Human epidermal growth factor receptor 2 is a member of human epidermal growth factor receptors, ove...
The use of targeted therapy directed against HER2 is currently the standard of care in patients with...
The median survival of patients with HER2-positive metastatic breast cancer has more than doubled si...
BACKGROUND: Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in ad...
The human epidermal growth factor receptor 2 (HER2) is overexpressed/amplified in up to 25% of breas...
Aims and background. Trastuzumab, a humanized monoclonal antibody directed against the extracellula...
Metastatic breast cancer is an incurable disease in a very high percentage of patients. Despite new ...
With the exception of endocrine therapy, no other systemic treatment of patients with breast cancer ...
In 2020, approximately 18,000 women in Poland were diagnosed with breast cancer, and 6,000 of them d...
Background Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in adv...
Targeted therapies are causing a dramatic change in cancer drug development. Trastuzumab, a humanise...
近年来,HER2及其单克隆抗体trastuzumab(商品名Herceptin)是乳腺癌研究的热点之一.被认为是一新的判断乳腺癌预后的独立标志物和治疗靶点.抗HER2的单抗trastuzumab对晚期...
Overexpression of the receptor for human epidermal growth factor type 2 (HER2), or gene amplificatio...
Objective: To observe the efficacy and safety of trastuzumab combined with chemotherapy in patients ...
HER2阳性乳腺癌分子靶向治疗一线药物(曲妥珠单抗)的耐药现象一直是临床治疗的难题.主要机制有曲妥珠单抗与HER2的有效结合受阻;PI3K/AKT/mTOR信号通路异常活化;IGF-1R高水平表达、上...
Human epidermal growth factor receptor 2 is a member of human epidermal growth factor receptors, ove...
The use of targeted therapy directed against HER2 is currently the standard of care in patients with...
The median survival of patients with HER2-positive metastatic breast cancer has more than doubled si...
BACKGROUND: Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in ad...
The human epidermal growth factor receptor 2 (HER2) is overexpressed/amplified in up to 25% of breas...
Aims and background. Trastuzumab, a humanized monoclonal antibody directed against the extracellula...
Metastatic breast cancer is an incurable disease in a very high percentage of patients. Despite new ...
With the exception of endocrine therapy, no other systemic treatment of patients with breast cancer ...
In 2020, approximately 18,000 women in Poland were diagnosed with breast cancer, and 6,000 of them d...
Background Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in adv...
Targeted therapies are causing a dramatic change in cancer drug development. Trastuzumab, a humanise...
近年来,HER2及其单克隆抗体trastuzumab(商品名Herceptin)是乳腺癌研究的热点之一.被认为是一新的判断乳腺癌预后的独立标志物和治疗靶点.抗HER2的单抗trastuzumab对晚期...
Overexpression of the receptor for human epidermal growth factor type 2 (HER2), or gene amplificatio...